Rotavirus vaccines: Safety, efficacy and public health impact

Journal of Internal Medicine

Volumn 270, Issue 3, 2011, Pages 206-214

  Gray, J ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Efficacy; Rotavirus vaccine; Safety

Indexed keywords

ROTAVIRUS NONSTRUCTURAL PROTEIN 4; ROTAVIRUS VACCINE;

ACUTE GASTROENTERITIS; ARTICLE; DEHYDRATION; DEVELOPING COUNTRY; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EMERGENCY WARD; FEVER; HUMAN; IRRITABILITY; MORTALITY; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; ROTAVIRUS; ROTAVIRUS INFECTION; SIDE EFFECT; VOMITING;

AMERICAS; AUSTRALIA; DIARRHEA; EUROPE; FLUID THERAPY; GASTROENTERITIS; HUMANS; IMMUNITY, HERD; INFANT; MASS VACCINATION; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED; WORLD HEALTH;

EID: 80051570962     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02409.x     Document Type: Article

References (27)

1. Iturriza-Gómara M, Kang G, Gray J. Rotavirus genotyping. Keeping up with an evolving population of human rotaviruses. J Clin Virol 2004; 31: 259-65.
2. Rennels MB, Glass RI, Dennehy PH et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996; 97: 7-13.
3. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354: 11-22.
4. Vesikari T, Matson DO, Dennehy P et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354: 23-33.
5. Centers for Disease Control and Prevention. Suspension of rotavirus vaccine after reports of intussusception - United States, 1999. MMWR Recomm Rep 2004; 53: 786-9.
6. Phua KB, Lim FS, Lau YL et al. Safety and efficacy of human rotavirus vaccine during the first 2years of life in Asian infants: randomised, double-blind, controlled study. Vaccine 2009; 27: 5936-41.
7. Armah GE, Sow SO, Breiman RF et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376: 606-14.
8. Zaman K, Anh DD, Victor JC et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376: 615-23.
9. Madhi SA, Cunliffe NA, Steele D et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362: 289-98.
10. Iturriza-Gómara M, Dallman T, Bányai K et al. Rotavirus genotypes co-circulating in Europe between 2006 and 2009 as determined by EuroRotaNet, a pan-European collaborative strain surveillance network. Epidemiol Infect 2011; 139: 895-909.
11. Curns AT, Panozzo CA, Tate JE et al. Remarkable postvacination spatiotemperal changes in United States rotavirus activity. Pediatr Infect Dis J 2011; 30: S54-5.
12. Buttery JP, Lambert SB, Grimwood K, Lambert SB. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's national childhood vaccine schedule. Pediatr Infect Dis J 2011; 30: S25-9.
13. Field EJ, Vally H, Grimwood K et al. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics 2010; 126: e506-12.
14. Lambert SB, Faux CE, Hall L et al.. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. Med J Australia 2009; 191: 157-60.
15. Braeckman T, Van Herck K, Raes M, Vergison A, Sabbe M, Van Damme P. Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J 2011; 30: S21-4.
16. Lanzieri TM, Linhares AC, Costa I et al. Impact of rotavirus vaccination on childhood deaths from diarrhea in Brazil. Int J Infect Dis 2011; 15: e206-10.
17. Ikedo do Carmo GM, Yen C, Cortes J et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLOS Medicine 2011; 8: 1-11.
18. Yen C, Tate JE, Wenk JD, Harris JM 2nd, Parashar UD. Diarrhea-associated hospitalisations among US children over 2 rotavirus seasons after vaccine introduction. Pediatrics 2011; 127: e9-15.
19. Vesikari T, Karvonen A, Ferrante SA, Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, TotaTeq®in Finnish infants up to 3years of age: the Finnish Extension Study. Eur J Pediatr 2010; 169: 1379-86.
20. Richardson V, Hernandez-Pichardo, Quintanar-Solares M et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 2010; 362: 299-305.
21. Quintanar-Solares M, Yen C, Richardson V, Esparza-Aguilar M, Parashar UD, Patel MM. Impact of rotavirus vaccination on diarrhea-related hospitalizations among children <5years of age in Mexico. Pediatr Infect Dis J 2011; 30: S11-5.
22. Molto Y, Cortes JE, De Oliveira LH et al. Reduction of diarrhea-associated hospitalizations among children aged < 5years in Panama following the introduction of rotavirus vaccine. Pediatr Infect Dis J 2011; 30: S16-20.
23. Tate JE, Cortese MM, Payne DC et al. Uptake, impact and effectiveness of rotavirus vaccination in the United States. Pediatr Infect Dis J 2011; 30: S56-60.
24. Wang FT, Mast TC, Glass RJ et al. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010; 125: e208-13.
25. Tate JE, Mutuc JD, Panozzo CA et al. Sustained decline in rotavirus detections in the United States following the introduction of rotavirus vaccine in 2006. Pediatr Infect Dis J 2011; 30: S30-4.
26. Bégué RE, Perrin K. Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice. Pediatrics 2010; 126: e40-5.
27. Boom JA, Tate JE, Sahni LC et al. Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital. Pediatr Infect Dis J 2010; 29: 1133-5.